Drugs that contain Dacomitinib

1. List of Vizimpro drug patents

VIZIMPRO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(1 year, 11 months from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(2 years from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(2 years from now)

Do you want to check out VIZIMPRO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 27, 2025
New Chemical Entity Exclusivity (NCE) Sep 27, 2023

NCE-1 date: 2022-09-27

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a u...

Dosage: TABLET;ORAL

More Information on Dosage

VIZIMPRO family patents

10

United States

8

China

3

Israel

3

Korea, Republic of

3

Japan

3

Norway

2

Luxembourg

2

Australia

2

Canada

2

New Zealand

2

Denmark

2

Spain

2

Austria

2

Nicaragua

2

Cyprus

2

Portugal

2

Russia

2

Poland

2

Hong Kong

2

Slovenia

2

Mexico

2

Brazil

2

South Africa

2

Hungary

2

European Union

1

Panama

1

Ecuador

AP

1

AP

EA

1

EA

1

Croatia

IB

1

IB

1

Netherlands

1

Honduras

1

Tunisia

1

Uruguay

1

Peru

1

Malaysia

1

Costa Rica

1

ME

1

Ukraine

1

Morocco

1

Georgia

1

Guatemala

1

Argentina

1

RS

1

Germany

1

Taiwan

1

Lithuania

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic